A record of what Vikas Khemani said publicly, with the source. Not advice.
Pending — not yet graded
“Carnelian maintains large, untrimmed positions in pharma and CDMOs, viewing CDMOs as a robust long-term manufacturing theme. Biosimilars present a significant opportunity over the next five to seven years, while the broader pharma sector serves as a defensive anchor now and a growth story later.”
Nifty PharmaBullishCalled 24 Mar 2026
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Vikas Khemani’s full track record